Eli Lilly wants to take big swings in Alzheimer’s, ALS, chronic pain and other difficult diseases after its success in ...

Detailed price information for Eli Lilly and Company (LLY-N) from The Globe and Mail including charting and trades.

Eli Lilly is paying up to $630m for a Phase I metabolic-associated ... The drugmaker’s blockbuster GLP-1RA drug tirzepatide – ...

Eli Lilly continues to see strong growth coming from its GLP-1 drugs. The company's current 2025 guidance looks conservative.

Shortages of Ozempic and Wegovy that have been in place for more than two years have been resolved, as supplies of the popular diabetes and obesity treatments continue to improve, federal ...

Eli Lilly has begun the week with a bang. Early Monday morning, AdvanCell and OliX Pharmaceuticals put out news that the Big ...

Eli Lilly and Company (NYSE ... Mounjaro and Zepbound both contain the same drug, tirzepatide. Mounjaro helps treat type 2 diabetes, while Zepbound is for obesity. Mounjaro sales rose 60% compared ...

Eli Lilly and RNAi therapeutics specialist OliX Pharmaceuticals have entered into a global licensing agreement to advance a ...

On the top-line, Lilly’s revenue grew by 45% ... Mounjaro and Zepbound both contain the same drug, tirzepatide. Mounjaro helps treat type 2 diabetes, while Zepbound is for obesity.